Transcriptome-Wide Gene Expression Profiles from FFPE Materials Based on a Nuclease Protection Assay Reveals Significantly Different Patterns between Synovial Sarcomas and Morphologic Mimickers.

FFPE HTG EdgeSeq biomarker extraction-free RNA workflow nuclease protection assay transcriptome profiling

Journal

Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829

Informations de publication

Date de publication:
28 Sep 2022
Historique:
received: 26 07 2022
revised: 30 08 2022
accepted: 09 09 2022
entrez: 14 10 2022
pubmed: 15 10 2022
medline: 15 10 2022
Statut: epublish

Résumé

Transcriptome profiling provides large data on tumor biology, which is particularly valuable in translational research and is becoming more and more important for clinical decision-making as well. RNA sequencing is considered to be the gold standard for this. However, FFPE material, as the most available material in routine pathology, has been an undefeatable obstacle for RNAseq. Extraction-free nuclease protection assays have the potential to be a reliable alternative method for large-scale expression profiling. The aim of this study was to validate and test the basic feasibility, technical applicability robustness, and reliability of the HTG transcriptome profiling (HTP) assay on clinical tumor samples. FFPE samples from 44 synovial sarcomas (SyS) and 20 spindle cell sarcomas (SpcS) were used. The HTP assay was performed on 10 µm thin FFPE slides. After nuclease protection in the HTG Edge Seq System, libraries were generated for sequencing on an Illumina NextSeq 500 platform. Fastq data were parsed and then analyzed by using the HTG analysis platform EdgeSeq REVEAL. Immunohistochemistry was performed to validate the expression of TLE1. The technical application of the HTP Panel revealed robust and reliable results with 62 samples, and only 2 samples failed due to an incomplete digestion of gDNA. The analysis, performed at the analysis platform REVEAL, showed 5964 genes being significantly differentially expressed between SpcS and SyS. In particular, overexpression of the known marker TLE1 in synovial sarcoma could be recovered, which underlines the reliability of this system. Transcriptome profiling gets more and more important for tumor research and diagnostics. Among other established technologies, the HTP Panel has shown to be a feasible method to get robust and reliable results. Thereby, this method needs very few sample-input by getting a success-rate of 96.88%, which indicates the upper average range, compared to other technologies working with FFPE tissue. The nuclease protection assay-based HTP Panel is a feasible method for adequate transcriptome profiling with low sample input and therefore is suitable for further research of biomarkers.

Sections du résumé

BACKGROUND BACKGROUND
Transcriptome profiling provides large data on tumor biology, which is particularly valuable in translational research and is becoming more and more important for clinical decision-making as well. RNA sequencing is considered to be the gold standard for this. However, FFPE material, as the most available material in routine pathology, has been an undefeatable obstacle for RNAseq. Extraction-free nuclease protection assays have the potential to be a reliable alternative method for large-scale expression profiling. The aim of this study was to validate and test the basic feasibility, technical applicability robustness, and reliability of the HTG transcriptome profiling (HTP) assay on clinical tumor samples.
METHODS METHODS
FFPE samples from 44 synovial sarcomas (SyS) and 20 spindle cell sarcomas (SpcS) were used. The HTP assay was performed on 10 µm thin FFPE slides. After nuclease protection in the HTG Edge Seq System, libraries were generated for sequencing on an Illumina NextSeq 500 platform. Fastq data were parsed and then analyzed by using the HTG analysis platform EdgeSeq REVEAL. Immunohistochemistry was performed to validate the expression of TLE1.
RESULTS RESULTS
The technical application of the HTP Panel revealed robust and reliable results with 62 samples, and only 2 samples failed due to an incomplete digestion of gDNA. The analysis, performed at the analysis platform REVEAL, showed 5964 genes being significantly differentially expressed between SpcS and SyS. In particular, overexpression of the known marker TLE1 in synovial sarcoma could be recovered, which underlines the reliability of this system.
DISCUSSION CONCLUSIONS
Transcriptome profiling gets more and more important for tumor research and diagnostics. Among other established technologies, the HTP Panel has shown to be a feasible method to get robust and reliable results. Thereby, this method needs very few sample-input by getting a success-rate of 96.88%, which indicates the upper average range, compared to other technologies working with FFPE tissue.
CONCLUSION CONCLUSIONS
The nuclease protection assay-based HTP Panel is a feasible method for adequate transcriptome profiling with low sample input and therefore is suitable for further research of biomarkers.

Identifiants

pubmed: 36230659
pii: cancers14194737
doi: 10.3390/cancers14194737
pmc: PMC9563597
pii:
doi:

Types de publication

Journal Article

Langues

eng

Déclaration de conflit d'intérêts

This work was supported by HTG Molecular. Rainer Hamacher reports travel grants from Lilly, Novartis, and PharmaMar as well as personal fees from Lilly and PharmaMar outside of the submitted work. Sabrina Borchert reports fees from Brystol-Myers Squibb (research funding) outside of the submitted work. The other authors declare no potential conflicts of interest.

Références

Oncogene. 2016 Sep 22;35(38):5021-32
pubmed: 26947017
Sarcoma. 2020 Jan 29;2020:7192347
pubmed: 32322158
PLoS One. 2017 Jan 25;12(1):e0170632
pubmed: 28122052
Biotech Histochem. 2018;93(5):373-386
pubmed: 30113239
J Gastrointest Oncol. 2020 Aug;11(4):695-707
pubmed: 32953153
Int J Mol Sci. 2016 May 13;17(5):
pubmed: 27187374
Appl Immunohistochem Mol Morphol. 2007 Sep;15(3):338-42
pubmed: 17721281
Oncotarget. 2018 Feb 28;9(21):15705-15720
pubmed: 29644003
BMC Bioinformatics. 2020 Jan 28;21(1):30
pubmed: 31992186
Front Cell Dev Biol. 2018 Jun 28;6:66
pubmed: 30003082
Prog Lipid Res. 2016 Jan;61:134-48
pubmed: 26708865
Clin Cancer Res. 2012 Nov 1;18(21):5850-5
pubmed: 22952346
PLoS One. 2007 Dec 05;2(12):e1261
pubmed: 18060057
PLoS One. 2019 Feb 22;14(2):e0212031
pubmed: 30794557
Pathol Res Pract. 2019 Feb;215(2):381-386
pubmed: 30606660
PLoS One. 2013 Jul 31;8(7):e70714
pubmed: 23936242

Auteurs

Sabrina Borchert (S)

Institute of Pathology, University Hospital Essen, Hufelandstraße 55, D-45147 Essen, Germany.
German Cancer Consortium (DKTK), Partner Site University Hospital Essen, D-45147 Essen, Germany.

Thomas Herold (T)

Institute of Pathology, University Hospital Essen, Hufelandstraße 55, D-45147 Essen, Germany.
German Cancer Consortium (DKTK), Partner Site University Hospital Essen, D-45147 Essen, Germany.

Stavros Kalbourtzis (S)

Institute of Pathology, University Hospital Essen, Hufelandstraße 55, D-45147 Essen, Germany.
German Cancer Consortium (DKTK), Partner Site University Hospital Essen, D-45147 Essen, Germany.

Rainer Hamacher (R)

German Cancer Consortium (DKTK), Partner Site University Hospital Essen, D-45147 Essen, Germany.
Department of Medical Oncology, Sarcoma Center, West German Cancer Center, University Hospital Essen, D-45147 Essen, Germany.

Yvonne Krause (Y)

Institute of Pathology, University Hospital Essen, Hufelandstraße 55, D-45147 Essen, Germany.
German Cancer Consortium (DKTK), Partner Site University Hospital Essen, D-45147 Essen, Germany.

Sophia Berger (S)

Institute of Pathology, University Hospital Essen, Hufelandstraße 55, D-45147 Essen, Germany.
German Cancer Consortium (DKTK), Partner Site University Hospital Essen, D-45147 Essen, Germany.

Wiebke K Guder (WK)

German Cancer Consortium (DKTK), Partner Site University Hospital Essen, D-45147 Essen, Germany.
Department of Orthopedics and Tumor Orthopedics, University Hospital Muenster, 48149 Muenster, Germany.
Department of Orthopedic Oncology, University Hospital Essen, D-45147 Essen, Germany.

Arne Streitbuerger (A)

German Cancer Consortium (DKTK), Partner Site University Hospital Essen, D-45147 Essen, Germany.
Department of Orthopedic Oncology, University Hospital Essen, D-45147 Essen, Germany.

Jendrik Hardes (J)

German Cancer Consortium (DKTK), Partner Site University Hospital Essen, D-45147 Essen, Germany.
Department of Orthopedic Oncology, University Hospital Essen, D-45147 Essen, Germany.
Department of Musculoskeletal Oncology, University Hospital Essen, D-45147 Essen, Germany.

Moritz Goetz (M)

Center of Pathology, Cytology and Molecular Pathology, D-41462 Neuss, Germany.

Sebastian Bauer (S)

German Cancer Consortium (DKTK), Partner Site University Hospital Essen, D-45147 Essen, Germany.
Department of Medical Oncology, Sarcoma Center, West German Cancer Center, University Hospital Essen, D-45147 Essen, Germany.

Hans-Ulrich Schildhaus (HU)

Institute of Pathology, University Hospital Essen, Hufelandstraße 55, D-45147 Essen, Germany.
German Cancer Consortium (DKTK), Partner Site University Hospital Essen, D-45147 Essen, Germany.
Department of Medical Oncology, Sarcoma Center, West German Cancer Center, University Hospital Essen, D-45147 Essen, Germany.

Classifications MeSH